Microcap Confidential seems to be all the rage right now, so I couldn’t resist digging in to see what the hype is all about. Take a peek at my Microcap Confidential review to get the whole scoop. Give it a read, it’s pretty entertaining (if I do say so myself).
Presidential election, overseas conflicts, and the Magnificent Seven are the prominent topics of discussion in the mainstream media. But something much more impactful is playing out behind the scenes. During the last urgent stock update Joel Litman and Porter Stansberry shared a powerful secret … A historic anomaly that will create fortunes for those tracking it.
Microcap Confidential Review Key Takeaways
- This historic anomaly only exists because of today’s interest-rate environment. Feds manipulated the market by keeping rates artificially low (near zero) from the crash of 2008 until 2022. During this time the prices of some stocks soared for no reason. You know what happened to those stocks when interest rates were increased in record time in 2022. Dozens of them, if not hundreds, crashed over 90%.
- When the market is collapsing, investors rarely carefully consider which stocks to sell—instead, they sell everything. As a result, some fantastic companies became undervalued. It is called a negative enterprise value. Or negative-EV stocks, for short. Exactly these stocks surge after people realized the truth.
- However, not every one of those undervalued stocks rebounded yet. And therein lies this opportunity. Read further our Microcap Confidential Review for surprising details.
Microcap Confidential Review: What Are “Net-Net” companies?
“Net-Net” companies are businesses whose stock is selling at such a cheap price that their liquid assets (cash on hand, accounts receivable, inventories, net of all obligations) exceed their market value.
Porter, Joel and their team searched through the universe of companies we currently have and located every company that experienced this in the previous 25 years.
Then they researched the performance of those companies over a period of time.
Typically, the number of “net-net” companies is close to zero as you can see on the graph. Their number increased after the dot-com crash, right after the financial crisis in 2008, and during the bear market we experienced in 2018.
Today their number is much higher than anything we’ve seen before. That’s why I’m hoping that everyone is understanding just how rare this situation is.
In a market that functions well, this kind of scenario really shouldn’t exist. And it’s quite uncommon at a time like now when the stock market is highly priced.
Currently more than 250 stocks are in this situation, mostly in one corner of the market. Some of them could be incredible investments going forward.
Microcap Confidential Review: Where Is The Anomaly?
Trying to tame inflation in 2022 the Fed aggressively pushed interest rates up at the fastest pace in history. From close to zero to over 5% in less than a year.
The pressure of such interest rates was simply too much for the market to handle. Major indexes had their worst year since 2008. The S&P 500 lost 20%, the tech-heavy Nasdaq Composite lost 33%.
The sector that was completely washed out was Biotech. It fell 62% from its peak. Of the 600 listed biotechnology stocks, 402 have dropped by 80% or more, making up more than two thirds.
To finance the development of new drugs, biotech companies mainly depend on investors. As a result of the Fed’s interest rate hikes investors lost interest in continuing to fund these enterprises.
Bottom Line: The number of net-net companies in the biotech industry has reached a record high. Currently, over 250 biotech businesses in the market are facing this situation.
On the other side, the little biotech companies with dropping share values may be among the most creative life-sciences companies our nation has ever generated, thanks to the combination of medical discoveries and artificial intelligence advancements. As Joel said, “This is where you’ll find the real AI plays… and the real stocks that SHOULD be soaring hundreds of percent.”
Microcap Confidential Buyout Opportunities
Porter and Joel believe these smaller biotech companies are being hunted by everyone on Wall Street.
Because these businesses are currently such a great deal, major pharmaceutical firms should consider these companies as obvious targets for acquisition.
A drug’s introduction to the market typically costs at least $1.3 billion.
Furthermore, the losses suffered by several biotech net-net companies are so great that their total market capitalization is below $100 million. Some even less.
Why then wouldn’t you purchase the business if you believe it is well-managed and has solid scientific foundations?
The worst-case scenario would be to sell off the company’s assets and make money out of it.
The Fed has made it clear that it plans to lower interest rates multiple times this year.
These companies are priced on expectations, their stocks will soar when interest rates drop down later this year. This is the reason why we only have a limited window of opportunity.
Porter and Joel admitted that normally they would not recommend biotech. Here is some info about their area of expertise.
Who is Porter Stansberry?
When Porter discovers an anomaly such as this one, his followers know that those who are able to fully grasp the significance of his findings and have the courage to take action are frequently highly rewarded.
Prior to the Great Recession, he made public statements predicting that Fannie Mae and Freddie Mac, the two biggest mortgage brokers in the world, were going toward bankruptcy.
Porter recognized another enormous opportunity in distressed debt in 2015. He had a 100% success rate on his suggestions that year, and the “boring bonds” he recommended had average gains of 27%.
Despite Porter’s past performance, he now believes this anomaly is “the single greatest opportunity” he has seen in his entire career.
Who Is Joel Litman, CPA?
He is the chief investment strategist of Valens Research, an institutional investment research organization. Litman frequently speaks at the London School of Economics, Harvard, MIT, and Wharton.
Among his followers are the top 10 global investment houses and more than half of the world’s top 300 money managers.
He has even served as a consultant for the Pentagon, the FBI, the Marine Corps War College, and the U.S. Department of Defense.
Altimetry’s Top Negative-EV Picks: Microcap Confidential Review
First Altimetry’s team allocated the 250 net-net biotech companies, and they drilled down to the 115 of those stocks that appeared to be negative-EV.
They further applied their analysis for all the 115 negative-EV biotech. There is no surprise that nearly half the companies really weren’t negative-EV. Because GAAP accounting allows for what’s called “hidden debt.” Things like operating-lease debt, pension obligations, stock-option claims, preferred stock, and other liabilities.
Next was to eliminate other red flags like management issues, questionable activity, etc. They also looked at other stakeholders in the business.
Finally, after 2 months of hard work, they are recommending taking a venture-capital-like approach. They’ve included all their findings, titles and ticker symbols of their top five negative-EV biotech prospects, in a recently released report called “Altimetry’s Best Negative-EV Biotech Opportunities for 2024.“
It is advised that you do not pick a single stock. Rather spreading your investment on each one of them. Additionally, you will receive a watchlist of six more negative-EV biotech companies to keep a close eye on. You’ll get an alert when it’s time to take action.
If you are interested in taking advantage of this rare market situation and invest in the negative-EV biotech companies, you’ll need to join Joel’s research service that is COMMITTED to identifying large potential in the tiniest stocks in the world. It’s called Microcap Confidential.
Microcap Confidential Review: Overview
Microcap Confidential is where Joel and his team make monthly recommendations of a tiny stock, which they believe has MASSIVE upside potential. Since its launch, Microcap Confidential has doubled the return of the Russell 2000 Index, its benchmark!
You’ll get insights you’ll never find anywhere else outside of Wall Street. You’ll know the exact time to take any profits on these recommendations. All with the help of the Altimeter Pro.
By accepting this invitation, you will join a whole new world of opportunities. With this offer you will receive $8,899 worth of research, recommendations, and FREE bonuses.
Joel Litman also offers his members a 100% satisfaction guarantee, which I’ll discuss in detail later in our Microcap Confidential review, so you can join with confidence.
Next, our Microcap Confidential review will take a deep dive into everything that’s included in the Best Negative-EV Biotech Opportunities for 2024 offer. Here’s what you get…
Microcap Confidential Review: What Comes with Your Membership?
- 50% OFF One Year of Microcap Confidential ($5,000 value). Special price for a limited time $2,500. Currently there are THREE 100%+ open recommendations.
- BONUS: Altimetry’s Best Negative-EV Biotech Opportunities for 2024. Each one of the stocks in this report could at least double your money in the next year. Some could soar as much as 500% or higher.
- BONUS: Biotech Torpedoes: The Companies to Avoid at All Costs. Joel and his team uncovered 5 biotech companies which they urge you to avoid at all costs.
- BONUS: Microcap Forensics: How to Make 100% to 500% Gains on the Smallest Companies. This will be your quick guide for your new subscription.
- BONUS: One FREE Year of access to the Altimeter Pro ($1,200 value). You can enter more than 5,000 tickers into Joel’s legendary system, and instantly learn company’s TRUE earning power.
- BONUS: The Buffett Blueprint ($2,500 value). Joel detailed the #1 risk to the market right now and the safest place to invest your money for the long term.
- BONUS: One FREE Year of Timetable Investor ($199 value). In this monthly newsletter, Rob Spivey, Director of Research, summarizes market signals his team is seeing and how you should position yourself for the next 3 to 24 months.
- PLUS: 100% Satisfaction Guarantee. Microcap Confidential does not offer cash refunds, but if you are not happy for any reason, contact the Member Services team within 30 days and receive a FULL refund in a form of credit.
- A library full of reports, issues, and videos from Joel.
Microcap Confidential Review: Is It Legit?
For those of you not familiar with Porter and Joel’s work, the cornerstone of everything they do at Altimetry is finding the truth.
As Joel Litman said “If I’ve learned anything in my career, it is that the mainstream media lies. Hedge funds lie. Politicians lie. But numbers and data simply cannot lie…”
Litman is one of the very few people that often talk how GAAP accounting principles are terribly outdated. GAAP financial reports could be misleading, incomplete, and often completely incorrect.
Litman has dedicated his career to identifying GAAP accounting weaknesses and taking advantage of them for his and his clients’ benefit. He and his team apply a different set of rules, which allow them to get better picture of what’s really going on in the company.
You will rarely find such a deep and time-consuming analysis in other financial research companies.
Microcap Confidential Review Verdict
Because of this new anomaly in the financial markets, you have a second chance to see huge gains. It has nothing to do with a new virus, a stock market meltdown, or anything like this. In fact, the risk is much lower than it was at the height of the COVID crisis.
It comes down to a situation that shouldn’t exist in the financial markets: the opportunity to buy companies that are currently trading for LESS than the value of the cash and other assets they already own. You can potentially make hundreds-of-percent gains for just few days or months, not years.
To get started, you don’t have to learn a new asset class or technique, nor do you need a lot of funds. You’ll only need someone with the experience and resources to get you a list of these companies.
That’s it for our Microcap Confidential review. Click here for 50% off
